Progressive development in experimental models of transungual drug delivery of anti-fungal agents

被引:5
|
作者
Thatai, P. [1 ]
Tiwary, A. K. [1 ]
Sapra, B. [1 ]
机构
[1] Punjabi Univ, Dept Pharmaceut Sci & Drug Res, Div Pharmaceut, Patiala, Punjab, India
关键词
anti-fungal susceptibility testing; franz diffusion cell; permeation model; transungual; END-POINT DETERMINATIONS; IN-VITRO PERMEATION; ACETYL-L-CYSTEINE; HUMAN NAIL PLATE; EX-VIVO; IONTOPHORETIC TRANSPORT; BROTH MACRODILUTION; SUSCEPTIBILITY; PENETRATION; TERBINAFINE;
D O I
10.1111/ics.12230
中图分类号
O69 [应用化学];
学科分类号
081704 ;
摘要
Pre-clinical development comprises of different procedures that relate drug discovery in the laboratory for commencement of human clinical trials. Pre-clinical studies can be designed to recognize a lead candidate from a list to develop the procedure for scaleup, to choose the unsurpassed formulation, to determine the frequency, and duration of exposure; and eventually make the foundation of the anticipated clinical trial design. The foremost aim in the pharmaceutical research and industry is the claim of drug product quality throughout a drug's life cycle. The particulars of the pre-clinical development process for different candidates may vary; however, all have some common features. Typically in vitro, in vivo or ex vivo studies are elements of pre-clinical studies. Human pharmacokinetic in vivo studies are often supposed to serve as the ` gold standard' to assess product performance. On the other hand, when this general assumption is revisited, it appears that in vitro studies are occasionally better than in vivo studies in assessing dosage forms. The present review is compendious of different such models or approaches that can be used for designing and evalua tion of formulations for nail delivery with special reference to antifungal agents.
引用
收藏
页码:1 / 12
页数:12
相关论文
共 50 条
  • [1] Drug delivery system of anti-fungal and parasitic agents
    Maesaki, S
    CURRENT PHARMACEUTICAL DESIGN, 2002, 8 (06) : 433 - 440
  • [2] INTERACTION OF RIFAMPIN WITH OTHER ANTI-FUNGAL AGENTS IN EXPERIMENTAL MURINE CANDIDIASIS
    GRAYBILL, JR
    AHRENS, J
    REVIEWS OF INFECTIOUS DISEASES, 1983, 5 : S620 - S625
  • [3] The application of phenotypic microarray analysis to anti-fungal drug development
    Greetham, Darren
    Lappin, David F.
    Rajendran, Ranjith
    O'Donnell, Lindsay
    Sherry, Leighann
    Ramage, Gordon
    Nile, Christopher
    JOURNAL OF MICROBIOLOGICAL METHODS, 2017, 134 : 35 - 37
  • [4] Arrhythmias Associated with Administration of Anti-fungal Agents
    Hui, Wun Fung
    Hon, Kam Lun
    INDIAN PEDIATRICS, 2020, 57 (08) : 775 - 776
  • [5] Arrhythmias Associated with Administration of Anti-fungal Agents
    Wun Fung Hui
    Kam Lun Hon
    Indian Pediatrics, 2020, 57 : 775 - 776
  • [6] INVITRO LABORATORY EVALUATION OF ANTI-FUNGAL AGENTS
    SOMMER, B
    SHALISH, L
    SCHEWACHMILLET, M
    INTERNATIONAL JOURNAL OF DERMATOLOGY, 1983, 22 (05) : 336 - 336
  • [7] Emerging role of nanocarriers based topical delivery of anti-fungal agents in combating growing fungal infections
    Waghule, Tejashree
    Sankar, Shridula
    Rapalli, Vamshi Krishna
    Gorantla, Srividya
    Dubey, Sunil Kumar
    Chellappan, Dinesh Kumar
    Dua, Kamal
    Singhvi, Gautam
    DERMATOLOGIC THERAPY, 2020, 33 (06)
  • [8] Design and development of solid lipid nanoparticles for topical delivery of an anti-fungal agent
    Jain, Safal
    Jain, Sanjay
    Khare, Piush
    Gulbake, Arvind
    Bansal, Divya
    Jain, Sanjay K.
    DRUG DELIVERY, 2010, 17 (06) : 443 - 451
  • [9] The Development of Appropriate Dosage of Anti-bacterial and Anti-fungal Agents Based on Pharmacokinetics and Pharmacodynamics
    Matsumoto, Kazuaki
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2012, 132 (10): : 1171 - 1177
  • [10] Triazole hybrids as new type of anti-fungal agents
    Miniyar, Pankaj B.
    Mahajan, Anand A.
    Mokale, Santosh N.
    Shah, Mauli U.
    Kumar, Ashish S.
    Chaturbhuj, Ganesh U.
    ARABIAN JOURNAL OF CHEMISTRY, 2017, 10 (03) : 295 - 299